TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05835336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIZO Glasses
Description: Eyeglasses with personalized peripheral retinal stimuli
Study: NCT05076279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
Description: Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
Study: NCT04887610

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic preconditioning
Description: Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic preconditioning control
Description: Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low fat meal
Description: Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High fat meal
Description: Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
Study: NCT06366373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mental health art exhibition
Description: The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by Qixi Charity, an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: printed or online education materials
Description: The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
Study: NCT05124041

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rotational thromboelastometry
Description: ROTEM-guided protocol of hemostatic resuscitation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry
Description: ROTEM-guided protocol of hemostatic resuscitation
Study: NCT05832151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-102 Dose 15mg or 10mg
Description: 2 capsules twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules twice daily for 12 weeks
Study: NCT04649359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab (PF-06863135)
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab (PF-06863135)
Description: BCMA-CD3 bispecific antibody
Study: NCT05286554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin releasing hormone-agonist
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin releasing hormone-agonist
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
Study: NCT06292546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
Study: NCT04638075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental Nursing System
Description: The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
Study: NCT06486012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Photodynamic antibacterial dual-light device home-use with a marker substance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene
Description: Standard oral hygiene performed at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene
Description: Standard oral hygiene performed at home
Study: NCT06401759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcast
Description: Routine maintenance will be applied.
Study: NCT06251518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vimida
Description: Participants will receive access to the digital health intervention vimida in addition to TAU.
Study: NCT05014776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 10\^9 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
Study: NCT06565390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Babies in the Owlet monitor group
Description: The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state.
Study: NCT04354077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the NAc
Description: Deep Brain Stimulation of the Nucleus Accumbens
Study: NCT06565455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: La CASA (Comunidad, Alimentación, Seguridad y Amén) Program: Healthy Eating Intervention
Description: The intervention will consist of seven healthy eating culturally developed modules, which will be implemented/delivered in the participants home and two cooking demonstration/tasting workshops for the participants in the intervention group (mothers in the church setting and individual and collective goal settings for the intervention group.
Study: NCT05735834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Truxima concentrate for solution for infusion 500 mg/50 ml
Study: NCT06174597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UCA-PSCs/bFGF or bFGF Intramuscular injection
Description: After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UCA-PSCs/bFGF or bFGF Intramuscular injection
Description: After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
Study: NCT05735834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Truxima concentrate for solution for infusion 500 mg/50 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80 mg hard capsules
Study: NCT06245408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT05719558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1002
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1002
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1002
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1002
Description: intravenous (IV) infusion
Study: NCT06113471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral, Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, Tablet
Study: NCT05889182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets
Study: NCT06226883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (identical appearance to MORF-057) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Study: NCT05952453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: neoadjuvant treatment , followed by surgery, then maintenance chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparibp, embro
Description: maintenance chemotherapy : olaparib, pembro
Study: NCT05946941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06273917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIDE
Description: Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically.
Study: NCT05864950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
Study: NCT04539236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
Study: NCT06422806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo standard imaging scans

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Imaging
Description: Undergo standard imaging scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT06428942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-potassium vegetables
Description: low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
Study: NCT06422806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04557956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05439993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib plus paclitaxel
Description: Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
Study: NCT04557956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat Hydrobromide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat Hydrobromide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT06265584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG dosing platform when combined with standard tacrolimus and mini methotrexate
Description: On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
Study: NCT04799275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05523609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 20 patients will receive Letrozole only for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole + vitamin D3 and calcium
Description: 20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
Study: NCT04799275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT06569121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance for People Post Stroke (GLB-CVA)
Description: 12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
Study: NCT06113445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral, Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, Tablet
Study: NCT05761886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth-based clinical pharmacy intervention
Description: The pharmacist will perform an initial comprehensive review of the medication regimen, make any adjustments, document those in the patient's electronic health record (EHR) and communicate with the patient's T2D care team as needed. They will also call (using an EHR-based software) the patient using phone/video to educate them about T2D self-management and identify any medication-related unmet needs. Periodic reviews of the medication regimen and roughly biweekly follow-up patient calls will occur with frequency based on need (as judged by the pharmacist). Patient intervention calls will be personalized depending on HbA1c levels, comorbidities, and medication complexity